Tacrolimus topical - MC2 Therapeutics

Drug Profile

Tacrolimus topical - MC2 Therapeutics

Alternative Names: MC2 11; MC2-11 PAD™ Cream; PADeczema

Latest Information Update: 14 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MC2 Biotek
  • Developer MC2 Therapeutics
  • Class Lactones; Macrolides
  • Mechanism of Action Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Atopic dermatitis

Most Recent Events

  • 14 Feb 2017 Chemical structure information added
  • 25 Jan 2017 Preclinical trials in Atopic dermatitis in Germany (Topical) before January 2017
  • 25 Jan 2017 MC2 Therapeutics plans a phase II trial for Atopic dermatitis (MC2 Therapeutics pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top